BioCanRx invests $10M in cancer immunotherapy research and biomanufacturing
Funding will move novel cancer technologies from the lab to the clinic
OTTAWA — BioCanRx, Canada’s Immunotherapy Network, announced funding of $10M for 14 cancer immunotherapy research projects and eight core and biomanufacturing facilities.
In addition to BioCanRx’s investment, matching partner contributions of $16.5M increase the total investment in Canadian translational cancer immunotherapy research and manufacturing facilities to $26.5M.
“BioCanRx is translating immune-based technologies from the lab into early phase clinical trials,” said Stéphanie Michaud, President & CEO, BioCanRx, in a repared statement. “We’re also committed to working in parallel to address the socio-economic factors necessary for their adoption in the Canadian healthcare system.”
BioCanRx is working to turn the tide and improve outcomes for patients by accelerating the development of promising immunotherapy treatments which could be more effective, affordable and safe than conventional cancer therapies.
The focus of the newly funded projects includes novel approaches to cancer treatment, targeting difficult to treat cancers where current options are limited. The project investment portfolio includes cross-disciplinary teams from across the country working on new, rational combination approaches and unique cell, vaccine/virus-based and antibody immunotherapies.